Abatacept with FluBu2: To Use or Not to Use

In 2021, the FDA approved using abatacept (ABA) for acute graft versus host disease (aGVHD) prevention in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (SCT) from a matched (MUD) or 1 allele-mismatched unrelated donor (MMUD), based on the p...

Full description

Saved in:
Bibliographic Details
Published in:Transplantation and cellular therapy 2024-02, Vol.30 (2), p.S159-S159
Main Authors: Gonzalez-Mosquera, Luis F, Neme, Mrs. Klodiana, Mikulandric, Nancy, Mazur, Izabela, Emole, Josephine, Alavi, Asif, Peres, Edward, Abidi, Muneer H., Farhan, Shatha
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 2021, the FDA approved using abatacept (ABA) for acute graft versus host disease (aGVHD) prevention in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (SCT) from a matched (MUD) or 1 allele-mismatched unrelated donor (MMUD), based on the phase II ABA2 study. In that study, there was no difference in engraftment or relapse between patients who received ABA and those who did not. However, this study included a significant number of young patients (median age
ISSN:2666-6367
2666-6367
DOI:10.1016/j.jtct.2023.12.204